Related Experiment Video
Updated: Oct 3, 2025
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
Utility of Cell-Free DNA Detection in Transplant Oncology
Tejaswini Reddy1,2,3, Abdullah Esmail1,3, Jenny C Chang3,4
1Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77030, USA.
Abstract:
Transplant oncology is an emerging field in cancer treatment that applies transplant medicine, surgery, and oncology to improve cancer patient survival and quality of life. A critical concept that must be addressed to ensure the successful application of transplant oncology to patient care is efficient monitoring of tumor burden pre-and post-transplant and transplant rejection. Cell-free DNA (cfDNA) detection has emerged as a vital tool in revolutionizing the management of cancer patients who undergo organ transplantation. The advances in cfDNA technology have provided options to perform a pre-transplant evaluation of minimal residual disease (MRD) and post-transplant evaluation of cancer recurrence and transplant rejection. This review aims to provide a comprehensive overview of the history and emergence of cfDNA technology, its applications to specifically monitor tumor burden at pre-and post-transplant stages, and evaluate transplant rejection.
Insights
Cell-free DNA (cfDNA) monitoring revolutionizes transplant oncology by enabling efficient tumor burden assessment and rejection detection pre- and post-transplant, improving patient outcomes.
Area of Science:
- Oncology
- Transplant Medicine
- Molecular Diagnostics
Background:
- Transplant oncology integrates transplant medicine, surgery, and oncology to enhance cancer patient survival and quality of life.
- Efficient monitoring of tumor burden and transplant rejection is crucial for successful transplant oncology.
- Cell-free DNA (cfDNA) detection is a vital tool in managing cancer patients undergoing transplantation.
Purpose of the Study:
- To provide a comprehensive overview of cfDNA technology in transplant oncology.
- To detail the applications of cfDNA for monitoring tumor burden pre- and post-transplant.
- To review the use of cfDNA in evaluating transplant rejection.
Main Methods:
- Review of existing literature on cfDNA technology and its applications in transplant oncology.
- Analysis of cfDNA's role in minimal residual disease (MRD) detection.
- Examination of cfDNA's utility in assessing cancer recurrence and transplant rejection.
Main Results:
- cfDNA technology offers pre-transplant evaluation of minimal residual disease (MRD).
- cfDNA enables post-transplant monitoring for cancer recurrence.
- cfDNA aids in the detection and management of transplant rejection.
Conclusions:
- cfDNA detection is a transformative technology in transplant oncology.
- Efficient cfDNA monitoring improves patient management and outcomes.
- Further research into cfDNA applications will advance transplant oncology care.
